Dr. Stephen D. Anesi, MD

Dr. Anesi practices at Surgisite Boston - Waltham in Waltham, Massachusetts.

Dr. Anesi's NPI, 1003052788, was assigned on December 30, 2008. Dr. Anesi graduated from Keck School of Medicine of USC in 2006. Dr. Anesi holds Massachusetts license 243244.

Dr. Anesi's primary practice is Surgisite Boston - Waltham, at 1440 Main Street, Waltham, MA 02451. The practice phone is (781) 891-9300.

Dr. Anesi's primary practice is Surgisite Boston - Waltham in Waltham, Massachusetts. Dr. Anesi is also affiliated with Tufts Medical Center. The medical group on file is Retina Consultants of Worcester. Dmand AI also links Dr. Anesi to 1 more hospital, 2 group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Anesi practices, 5 sites in all. Vendor and product names are available with a free account.

Ophthalmology is Dr. Anesi's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Anesi is board certified in ophthalmology by the American Board of Ophthalmology. Dr. Anesi is licensed in Massachusetts.

Dmand AI lists age-related macular degeneration, cataract, cataract surgery with lens implant, cold sores or genital herpes, conjunctivitis, dry eye, eye infection or inflammation and eyelid inflammation among the conditions Dr. Anesi treats.

CMS data shows 11,513 Medicare services from Dr. Anesi across 53 procedure codes in 2024, for 852 Medicare patients. Medicare paid $845,873 for them.

CMS counts 852 Medicare patients who saw Dr. Anesi in 2024. The largest group is 65 to 74, with 370 patients. 71% of them have high cholesterol, and 66% have high blood pressure. 15% are also on Medicaid. Their average risk score is 1.14, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Anesi's median patient age at 68, with 60% women.

In 2024, Dr. Anesi wrote 4,913 Medicare Part D claims for 651 patients. 59% of them were for generic drugs. CMS names the drug for 4,638 of them, across 65 drugs with 11 or more claims each, at $12,815,140 in total drug cost. In 2023, CMS named 3,473 claims across 57 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Anesi for performance year 2024, reported as part of a group. Dr. Anesi accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 248 procedures of cataract surgery by Dr. Anesi, more than 87% of the clinicians it reports for that procedure.

Dmand AI links 41 papers to Dr. Anesi, published from 2015 to 2025. 2020 was the busiest year, with 9. The most frequent topics are Uveitis, Visual Acuity and Fluorescein Angiography. Dr. Anesi has published most often in Ocul Immunol Inflamm. Dr. Anesi's most frequent co-authors are Arash Maleki, MD, Peter Chang, MD and David Sc Chu, MD.

Dmand AI links Dr. Anesi to 11 clinical trials, 4 of them phase 2 studies. 9 are still active or recruiting. Conditions studied include Adenocarcinoma of Lung, Biliary Atresia and Low Back Pain.

CMS Open Payments shows 1,374 general payments to Dr. Anesi from 47 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 77% of the total. Mallinckrodt Hospital Products Inc. paid the most, $616,327.

Dmand AI lists 1 award for Dr. Anesi, most recently CMS Stage 1 EHR in 2013.

Dr. Anesi graduated from Keck School of Medicine of USC in 2006. Dr. Anesi is a member of AAO and American Uveitis Society.

Dr. Anesi is in network with 16 carriers, including Aetna, Excellus BlueCross BlueShield and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.